An observational study in Relapsing Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Active, not recruiting. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Multiple Sclerosis by Novartis — 9 open to participants now, 24 under way, 6 of them phase 3. Multiple Sclerosis · Novartis.
Among the 106 studies in Multiple Sclerosis by Novartis, this one is the 34th largest by enrollment of the 41 observational ones that give a count, is one of 8 that started in 2023, is one of 41 observational ones, reaches primary completion later than 9 of the 23 other live ones, and was the 79th registered.
3,272 studies on the registry are indexed under Multiple Sclerosis; 664 are open to participants now.
Browse Multiple Sclerosis studies →9 of the 106 studies in Multiple Sclerosis by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 33 more countries
Ages 18–65
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 16 more countries
Ages 40–70
Novartis Pharmaceuticals · Sites in Greece
Ages 18–55
Novartis Pharmaceuticals · Sites in Switzerland
Ages 18+ · Women only
By country, each count listing its studies:
Of the 432 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 213 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 23 · Phase 4 26
First in 2003; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is close to the median of 100 across 971 observational studies indexed under Multiple Sclerosis.
Median enrollment 147 across the 64 interventional studies, 312 across the 41 observational. Of the 78 that completed or were terminated, 45 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
5 of the studies in Multiple Sclerosis by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07821411Novartis PharmaceuticalsA Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and Japan | 2026-11-30 |
| NCT05776888Novartis PharmaceuticalsEarly Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years | 2026-12-16 |
| NCT07779460Novartis PharmaceuticalsA Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice | 2026-12-31 |
| NCT05809986Novartis PharmaceuticalsOfatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study | 2026-12-31 |
| NCT05090371Novartis PharmaceuticalsA Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation | 2027-04-13 |
Add all 5 to your calendar (.ics) → With an account.
Among the 106 studies in Multiple Sclerosis by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This non-interventional study aims to observe the effect of early versus late Ofatumumab treatment in RMS patients in a real-world setting in Austria over an observational period of 24 months.
This multi-center, observational study will describe the effects of Ofatumumab in 2 cohorts in a routine medical care setting. Cohort one will comprise patients who have started Ofatumumab early during their disease (treatment naive patients or those that started Ofatumumab within 3 years of first therapy initiation). Cohort two will include patients who have been on other DMTs (one or several) for a minimum of 3 years prior to switching to Ofatumumab. Patients in both cohorts will be observed for two years.
The study population will include male and female patients (aged ≥ 18 years) with a documented diagnosis of RMS and treated for at least 3 months with Ofatumumab
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients that, before initiation of Ofatumumab, were either treatment naive or have started their treatment for RMS with another disease modifying therapy (BRACE, teriflunomide or fumarates). Non-naive patients in this cohort must have started the use of Ofatumumab within 3 years after first DMT initiation.
Other: Ofatumumab
Patients that have been on BRACE and/or Teriflunomide and/or fumarates for at least three years or longer before the switch to Ofatumumab has been initiated.
Other: Ofatumumab
There is no treatment allocation. For both cohorts, only patients that have received Ofatumumab treatment for at least 3 months prior to inclusion in the study will be enrolled.
Proportion of patients demonstrating NEDA-3
Proportion and comparison of patients in both cohorts achieving NEDA-3 in the second year after treatment initiation, which refers to a comparison between month 12 and 24 after Ofatumumab treatment was initiated. NEDA-3 is defined by no confirmed MS relapse, no new or enlarging T2 lesions, no new Gadolinium-positive T1 lesions (in case Gadolinium was utilized), and no six-month confirmed disability worsening.
Time frame: from month 12 up to month 24
Proportion of patients displaying NEDA-3, as well as individual NEDA components
Proportion of patients displaying NEDA-3, as well as individual NEDA components (i) experiencing no confirmed clinical relapses, (ii) lack of diseases progression measured by expanded disability status scale (EDSS) and (iii) absence of new disease activity (new or enhancing T2 or Gadolinium-positive T1 lesions (in case Gadolinium was utilized)), respectively, in the first treatment year (Baseline to month 12), the second treatment year (month 12 to month 24) as well as over the whole study period (Baseline to month 24).
Time frame: Baseline, month 12, month 24
Proportion of patients permanently discontinuing Ofatumumab during the study
Proportion of patients permanently discontinuing Ofatumumab during the study, and reasons for discontinuation will be provided
Time frame: Up to 24 months
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2023 (actual). Primary completion is estimated for Dec 2026, 41 months after the start.
Of 91 industry-sponsored observational studies under Multiple Sclerosis, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 75. This study's planned 41 months is below that.
Counting every sponsor, half of 426 studies reached it within 41 months; a quarter within 15 and three quarters within 75.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Aug 2026 → Dec 2026 and completion Aug 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.